Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN2477590 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-BCL2-Associated X Protein (BAX) (AA 43-61) antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide, CPELALDPVPQDASTKKLSE, corresponding to amino acids 43-61 of human BAX.
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 43-61
- Isotype
- IgG
- Vial size
- 0.1 mL
Submitted references BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma.
Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance.
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.
[Labial dysfunction, or: good use of the Chateau four-pieces].
Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Garcia-Escudero A, Pareja Megia MJ, Montironi R, Lopez-Beltran A
Cancer letters 2007 Jun 8;250(2):292-9
Cancer letters 2007 Jun 8;250(2):292-9
Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance.
Condon LT, Ashman JN, Ell SR, Stafford ND, Greenman J, Cawkwell L
International journal of cancer. Journal international du cancer 2002 Aug 1;100(4):472-5
International journal of cancer. Journal international du cancer 2002 Aug 1;100(4):472-5
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.
Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC
Cancer research 1995 Oct 1;55(19):4471-8
Cancer research 1995 Oct 1;55(19):4471-8
[Labial dysfunction, or: good use of the Chateau four-pieces].
Soulet A
Revue d'orthopedie dento-faciale 1991;25(4):419-32
Revue d'orthopedie dento-faciale 1991;25(4):419-32
No comments: Submit comment
No validations: Submit validation data